Matthew Kulke, MD, director, Neuroendocrine and Carcinoid Tumors Program, Dana-Farber Cancer Institute, discusses treatment options on the horizon in the treatment of neuroendocrine tumors (NETs) during the 2017 NANETS Symposium.
Matthew Kulke, MD
Advertisement
Articles by Matthew Kulke, MD
Advertisement
Latest Updated Articles
Treatments on the Horizon in NETsPublished: November 1st 2017 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5
